Patient and disease characteristics
Characteristics . | Nonablative patients (n = 60) . | Ablative patients (n = 74) . | P . |
|---|---|---|---|
| Conditioning regimens, % | |||
| FLU + 200 cGy TBI | 100 | 0 | |
| CY + 1200 cGy TBI | 0 | 58 | |
| CY + 1320 cGy TBI | 0 | 14 | |
| BU + CY | 0 | 28 | |
| Postgrafting immunosuppression, % | |||
| CSP + 30 mg/kg/d MMF | 80 | 9 | |
| CSP + 45 mg/kg/d MMF | 20 | 0 | |
| CSP + MTX | 0 | 90 | |
| CSP + MTX + sirolimus | 0 | 1 | |
| Disease, % | |||
| MDS | 22 | 19 | |
| Acute leukemia | 20 | 34 | |
| CML | 18 | 36 | |
| NHL/HD | 20 | 3 | .0002 |
| MM | 8 | 0 | |
| CLL | 7 | 3 | |
| Other* | 5 | 5 | |
| Disease risk group, % | |||
| High | 78 | 59 | .02 |
| Low | 22 | 41 | |
| Greater than 2nd CR, relapse, or refractory, % | 40 | 16 | .002 |
| Age at transplantation | |||
| Median, y (range) | 54 (5-69) | 41 (1-58) | < .0001 |
| Age older than 55 y, % | 43 | 3 | < .0001 |
| Preceding cytotoxic regimens | |||
| Median no. | 3 (0-7) | 1 (0-8) | .01 |
| 3 or more regimens, % | 58 | 34 | .004 |
| Preceding ablative HCT, % | 33 | 4 | < .0001 |
| Autologous/allogeneic, % | 30/3 | 1/3 | |
| Hematopoietic cell source, % | |||
| G-PBMCs | 82 | 43 | < .0001 |
| Marrow | 18 | 57 | |
| CMV risk group, %† | |||
| Low | 25 | 39 | |
| Intermediate | 18 | 16 | |
| High | 57 | 45 | .16 |
| Sex of patients, % | |||
| Male/female | 62/38 | 47/53 | 0.10 |
| Sex of donors, % | |||
| Male/female | 62/38 | 55/45 | 0.45 |
Characteristics . | Nonablative patients (n = 60) . | Ablative patients (n = 74) . | P . |
|---|---|---|---|
| Conditioning regimens, % | |||
| FLU + 200 cGy TBI | 100 | 0 | |
| CY + 1200 cGy TBI | 0 | 58 | |
| CY + 1320 cGy TBI | 0 | 14 | |
| BU + CY | 0 | 28 | |
| Postgrafting immunosuppression, % | |||
| CSP + 30 mg/kg/d MMF | 80 | 9 | |
| CSP + 45 mg/kg/d MMF | 20 | 0 | |
| CSP + MTX | 0 | 90 | |
| CSP + MTX + sirolimus | 0 | 1 | |
| Disease, % | |||
| MDS | 22 | 19 | |
| Acute leukemia | 20 | 34 | |
| CML | 18 | 36 | |
| NHL/HD | 20 | 3 | .0002 |
| MM | 8 | 0 | |
| CLL | 7 | 3 | |
| Other* | 5 | 5 | |
| Disease risk group, % | |||
| High | 78 | 59 | .02 |
| Low | 22 | 41 | |
| Greater than 2nd CR, relapse, or refractory, % | 40 | 16 | .002 |
| Age at transplantation | |||
| Median, y (range) | 54 (5-69) | 41 (1-58) | < .0001 |
| Age older than 55 y, % | 43 | 3 | < .0001 |
| Preceding cytotoxic regimens | |||
| Median no. | 3 (0-7) | 1 (0-8) | .01 |
| 3 or more regimens, % | 58 | 34 | .004 |
| Preceding ablative HCT, % | 33 | 4 | < .0001 |
| Autologous/allogeneic, % | 30/3 | 1/3 | |
| Hematopoietic cell source, % | |||
| G-PBMCs | 82 | 43 | < .0001 |
| Marrow | 18 | 57 | |
| CMV risk group, %† | |||
| Low | 25 | 39 | |
| Intermediate | 18 | 16 | |
| High | 57 | 45 | .16 |
| Sex of patients, % | |||
| Male/female | 62/38 | 47/53 | 0.10 |
| Sex of donors, % | |||
| Male/female | 62/38 | 55/45 | 0.45 |
NHL indicates non-Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple myeloma; CLL, chronic lymphocytic leukemia; CR, complete remission.
Myelofibrosis; plasma cell leukemia; and Waldenström macroglobulinemia.
Low indicates both recipient and donor have negative CMV serostatus; intermediate, donor has positive whereas recipient has negative CMV serostatus; and high, recipient has positive CMV serostatus regardless of donor condition.